PAIN TREATMENT

摘要

The disclosure relates to an RNA interference (RNAi) agent and the use of that RNAi agent to treat chronic pain in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The DNA-directed RNA interference (ddRNAi) agent for inhibiting expression of one or more target sequences in a pain associated gene comprises, one or more effector sequence sequences and effector complement sequences of at least 17 nucleotides in length, wherein the effector sequence is substantially complementary to the predicted transcript of a target sequence within a pain associated gene.

主权项

1. A DNA-directed RNA interference (ddRNAi) agent for inhibiting expression of one or more target sequences in a pain associated gene, the ddRNAi agent comprising, in a 5′ to 3′ direction
a first effector sequence of at least 17 nucleotides in length; a first effector complement sequence, wherein the first effector complement sequence is substantially complementary to the first effector sequence and wherein the effector sequence is substantially complementary to a predicted transcript of a region of the target gene.